Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced that on October 1, 2025 its Compensation Committee granted inducement stock options to seven new employees totaling 1,289,600 shares under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $3.18 (equal to the closing price on the grant date), a 10-year term, and vest over four years (25% after one year, then monthly ratable vesting over 36 months), subject to continued service.

DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2025, the Compensation Committee of Taysha's Board of Directors granted seven new employees, in the aggregate, options to purchase 1,289,600 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $3.18 which is equal to the closing price of Taysha's common stock on the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

What did Taysha (TSHA) announce on October 1, 2025?

Taysha granted inducement stock options for 1,289,600 shares to seven new employees under Nasdaq Rule 5635(c)(4).

What is the exercise price and term for the TSHA inducement options?

The options have an exercise price of $3.18 and a 10-year term.

How do the TSHA options vest and when does vesting start?

Vesting is over 4 years: 25% at the first anniversary of the vesting commencement date, then monthly over 36 months, subject to continued service.

Under what plan were the TSHA inducement options granted?

They were granted under the Taysha Gene Therapies 2023 Inducement Plan as material inducements to employment.

Why did Taysha use Nasdaq Listing Rule 5635(c)(4) for these grants?

The grants were made as inducements to new employees in accordance with Nasdaq Listing Rule 5635(c)(4), as stated in the press release.

How many employees received inducement options in the TSHA announcement?

Seven new employees received the inducement stock options totaling 1,289,600 shares.